MedTrace Logo

Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-2)

NCT05224960 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2024-10-18

No results posted yet for this study

Summary

Decompensated cirrhosis has a high overall mortality rate. There is a large unmet need for safe and alternative therapeutic potions. This clinical trial is to inspect the efficiency and safety of mesenchymal stem cells (MSCs) therapy for decompensated cirrhosis.

Conditions

  • Decompensated Cirrhosis

Interventions

BIOLOGICAL

UC-MSCs

3 doses of UC-MSCs intravenously at day 1, day 8, day 15.

BIOLOGICAL

Placebo(solution without UC-MSCs)

3 doses of placebo intravenously at day 1, day 8, day 15.

Sponsors & Collaborators

  • Chinese PLA General Hospital

    collaborator OTHER

  • Shanghai Changzheng Hospital

    collaborator OTHER

  • LanZhou University

    collaborator OTHER

  • Jin Yin-tan Hospital

    collaborator UNKNOWN

  • Hainan Hospital of Chinese PLA General Hospital

    collaborator UNKNOWN

  • Vcanbio Cell and Gene Engineering Corp., Ltd.

    collaborator INDUSTRY

  • Third Affiliated Hospital, Sun Yat-Sen University

    collaborator OTHER

  • Xinjiang Kashi Area Number 1 Hospital

    collaborator UNKNOWN

  • Beijing 302 Hospital

    lead OTHER

Principal Investigators

  • Fu-Sheng Wang, MD, PhD · Beijing 302 Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-27
Primary Completion
2025-06-27
Completion
2027-06-20

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05224960 on ClinicalTrials.gov